Dyadic International (DYAI) Return on Capital Employed (2019 - 2026)
Dyadic International (DYAI) posted Return on Capital Employed of 124.58% for Q1 2026, down 23.35% sequentially from 100.99% in Q4 2025, and down 4145.0% YoY from 3.08% in Q1 2025.
Dyadic International (DYAI) Return on Capital Employed (2019 - 2026) Analysis & Trends
Dyadic International has reported Return on Capital Employed for 8 years, with the latest figure at 124.58% in Q1 2026.
- Quarterly Return on Capital Employed fell 4145.0% year-over-year to 124.58% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 124.58% (down 4145.0% YoY) and the FY2025 annual result came in at 115.07%, down 2603.0% from the prior year.
- Return on Capital Employed slipped to 124.58% in Q1 2026 per DYAI's latest filing, from 100.99% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 0.15% in Q2 2022 and troughed at 126.89% in Q4 2023.
- A 5-year average of 85.56% and a median of 84.93% in 2023 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2022 and 2023: Return on Capital Employed soared 1655443 bps in 2022, then tumbled 8478 bps in 2023.
- Over 5 years, Return on Capital Employed stood at 84.59% in 2022, then slumped by 50 bps to 126.89% in 2023, then surged by 41 bps to 74.51% in 2024, then tumbled by 36 bps to 100.99% in 2025, then dropped by 23 bps to 124.58% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 124.58%, 100.99%, and 122.78% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Dyadic International | 19.98 Mn | 19.98 Mn | - | -124.58% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -124.58% |
| Dec 31, 2025 | -100.99% |
| Sep 30, 2025 | -122.78% |
| Jun 30, 2025 | -125.47% |
| Mar 31, 2025 | -83.13% |
| Dec 31, 2024 | -74.51% |
| Sep 30, 2024 | -75.68% |
| Jun 30, 2024 | -83.00% |
| Mar 31, 2024 | -101.42% |
| Dec 31, 2023 | -126.89% |
| Sep 30, 2023 | -95.32% |
| Jun 30, 2023 | -84.93% |
| Mar 31, 2023 | -83.18% |
| Dec 31, 2022 | -84.59% |
| Sep 30, 2022 | -87.76% |
| Jun 30, 2022 | -0.15% |
| Mar 31, 2022 | -0.19% |
| Dec 31, 2021 | -16,639.02% |
| Sep 30, 2021 | -14,358.60% |
| Jun 30, 2021 | -13,828.28% |